Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Rusfertide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rusfertide Granted Breakthrough Status for Polycythemia Vera
    Rusfertide Granted Breakthrough Status for Polycythemia Vera

    25 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-25/rusfertide-receives-breakthrough-therapy-designation-for-treatment-of-erythrocytosis-in-patients-wit

    PHARMAWEB
    25 Aug 2025
    Share Share
    Protagonist & Takeda's ASCO Presentation on Ph 3 VERIFY Study
    Protagonist & Takeda's ASCO Presentation on Ph 3 VERIFY Study

    01 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250531031305/en/Protagonist-and-Takeda-Announce-ASCO-Plenary-Presentation-Highlighting-Full-32-Week-Results-from-Phase-3-VERIFY-Study-of-Rusfertide-Showing-Reductions-in-Phlebotomy-Improved-Hematocrit-Control-in-Polycythemia-Vera

    BUSINESSWIRE
    01 Jun 2025
    Share Share
    Protagonist, Takeda’s Rusfertide Ph 3 VERIFY Study Positive
    Protagonist, Takeda’s Rusfertide Ph 3 VERIFY Study Positive

    03 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250303474433/en

    BUSINESSWIRE
    03 Mar 2025
    Share Share
    Protagonist Hosts Investor Event On PV, Rusfertide In New York
    Protagonist Hosts Investor Event On PV, Rusfertide In New York

    29 Jan 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagonist-to-host-investor-event-with-kol-insights-on-polycythemia-v-975919

    ACCESSWIRE
    29 Jan 2025
    Share Share
    Takeda touts 6 pipeline assets with big sales potential
    Takeda touts 6 pipeline assets with big sales potential

    16 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jpm25-takeda-spotlights-6-later-stage-assets-could-subvert-entyvio-pressures-20b-collective

    FIERCE PHARMA
    16 Jan 2025
    Share Share
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress

    14 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=877298&lang=en

    ACCESSWIRE
    14 Jun 2024
    Share Share